Cramer Remix: From Friday
Abigail Stevenson | @A_StevensonCNBC
Friday, 20 Mar 2015 | 8:26 PM ET
Celladon Corp: "A Good Spec. I'm a Buyer, Willing to Go for it"
Do The DD FOLKS :
Advaxis and Merck Form Collaboration to Evaluate Investigational Combination of Two Novel Immunotherapy Candidates for Advanced Prostate Cancer
PRINCETON, N.J., Aug. 25, 2014 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, has entered into a clinical trial collaboration agreement with Merck, known as MSD outside the United States and Canada, through its subsidiaries, to evaluate the combination of Advaxis's Lm-LLO cancer immunotherapy, ADXS-PSA, with Merck's investigational anti PD-1 antibody, pembrolizumab.
By Paul M. Barrett -March 11, 2015
Second Sight’s ( EYES ) Argus II Retinal Prosthesis System is the first patented and approved retinal prothesis in the world. " Millions stand to benefit from this life-changing technology. "
J&J buys into Achillion's hep C pipeline for up to $1.1B
May 19, 2015 | By Damian Garde
Johnson & Johnson ($JNJ), fighting to keep up with the blockbuster race to launch quick cures for hepatitis C, has agreed to pay as much as $1.1 billion for the rights to Achillion Pharmaceuticals' ($ACHN) pipeline of antiviral treatments.
Under the deal, J&J is making a $225 million investment in its partner and promising up to $905 million in milestone payments in order to get its hands on a group of in-development hep C treatments. The plan is to develop Achillion's drugs in combination with one another and, ideally, come up with a regimen thatcan cure the infection in as few as four weeks. Leading the pipeline is ACH-3102, Achillion's Phase II NS5A inhibitor, followed by the complementary ACH-3422 and sovaprevir.
Many analysts and articles calling CLLS the Next BLUE, CLLS actually better,covers more types of cancers then BLUE.
Sentiment: Strong Buy
Updates on Biotech Stocks Celladon Corporation ( CLDN )Top line data due out on Systolic Heart Faiure.They have FDA Fast Track and Breakthrough Therapy Designations. We think this stock could see $80.
Updates on Biotech Stocks Celladon Corporation ( CLDN )Top line data due out on Systolic Heart Faiure.They have FDA Fast Track and Breakthrough Therapy Designations. We think this stock couldsee $80.
Biotech to see continued growth in 2015: HC Wainwright
by Mourad Haroutunian
Both Advaxis (NASDAQ:ADXS) has benefited from strong interest Marque Investors Adage Capital Management and T. Rowe Price Associates invested nearly $17 million into Advaxis
ADRO Market Opportunity $90 Billion. Novel Approach,Favorable Safety Profile. LINK
Excitement Among Proof-of-Concept Drug Companies Could Spill Over Into This Lesser-Known Name
Excitement from proof-of-concept stage drug companies like Aduro Biotech ( ADRO ) or Receptos (NASDAQ: RCPT) could spill over into the lesser-known Sunshine Heart (NASDAQ: SSH), whose device is in a pivotal study for the treatment of late-stage heart failure - a disease with prognosis as poor as the most aggressive cancers and no effective treatment options. The market opportunity is perhaps as largeas ~$90 Billion.Part of the reason Aduro has performed amicably is that their approach to treating cancer is novel and potentially offers a favorable safety profile, particularly when compared to standard of care.
Conference call to be held on Monday, May 11, 2015 at 5:00 p.m. Eastern Time
- Positive momentum on clinical trials and research continues- Multiple strategic transactions furtherstrengthen technology platform and capabilities
- Strong quarter-end cash position of $447.6 million